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1Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Clinical Neuroscience,
Karolinska Institutet, Stockholm, Sweden, 3Memory and Aging Center, University of California, San Francisco, San Francisco,
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24S-hydroxycholesterol (24OHC) and Tau are produced in neuronal cells and
neurodegeneration leads to increased flux of both of them into cerebrospinal fluid
(CSF). In the present study, CSF levels of 24OHC and 27S-hydroxycholesterol (27OHC)
along with those of Tau, P-Thr181-Tau and Aβ42 were measured in patients with early
Parkinson’s disease (PD), Corticobasal syndrome (CBS), Corticobasal Degeneration
(CBD), and controls. Using mouse models with increased or no formation of Tau protein
and increased production of 24OHC, we have also tested the hypothesis that there
is a direct association between neuronal turnover of 24OHC and Tau. The levels of
24OHC are increased, at a group level, in patients with PD or CBS. We found significant
correlations between levels of 24OHC and Tau or P-Thr181-Tau in CSF from patients
with PD, CBS or CBD. There were no similar correlations between 24OHC and Aβ42
in CSF from these patients. The neuronal levels of 24OHC were not altered in Tau
knockout or Tau overexpressing mice. Vice versa, Tau species levels were not changed
in Cyp46 overexpressing mice with increased neuronal levels of 24OHC. We conclude
that the strongly correlative fluxes of 24OHC and Tau from neuronal cells to CSF are
likely to be secondary to neurodegeneration and not due to direct interaction between
the two factors. We suggest that this high correlation reflects a rapid neurodegeneration
of specific neuronal subtypes with simultaneous release of 24OHC and Tau into the CSF.
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INTRODUCTION
In contrast to cholesterol itself its side-chain oxidized metabolites 24S-hydroxycholesterol
(24OHC) and 27-hydroxycholesterol (27OHC) are able to pass the blood-brain barrier. 24OHC is
exclusively formed in neurons and is continuously fluxed into the circulation (1). 27OHC is mainly
formed in extracerebral tissues and organs, but there is a continuous flux of this oxysterol from the
circulation into the brain (2). Neurodegeneration results in increased flux of 24OHC from neurons
into CSF, possibly due to a direct release from the decomposing cells (1). Neurodegeneration also
results in disruption of the blood-brain barrier and reduced capacity of the neuronal enzyme
CYP7B1 to metabolize 27OHC resulting to increased 27OHC in CSF (2).
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Evidence has accumulated that 24OHC in CSF can be used
as a biomarker for neurodegeneration, particularly at early stages
(3). Another commonly used biomarker for neurodegeneration
is Tau. The role of this protein is to stabilize axonal microtubule
by promoting tubulin assembly. Abnormal phosphorylation of
neuronal Tau leads to destabilization and increased levels of
Tau and phospho-Tau in CSF (4). In a previous study (5), we
found a significant correlation between Tau or P-Thr181-Tau and
24OHC in CSF from patients with Alzheimer’s disease and mild
cognitive impairment. This finding was confirmed in a later study
by another group (6).
Here, we have compared CSF levels of 24OHC and 27OHC
along with those of Tau, P-Thr181-Tau and Aβ42 in patients
with parkinsonism. Specifically, we have studied CSF samples
from patients with Parkinson’s disease (PD), which is a
synucleinopathy, but associated with genetic polymorphisms
regulation tau expression (7). We have also studied samples
from patients with Corticobasal syndrome (CBS), a condition
characterized by filamentous Tau inclusions in neurons and
astrocytes (8, 9). Since CBS encompasses a diagnostically
heterogeneous group of patients (8, 9), we also evaluated
CSF from pathologically confirmed cases with Corticobasal
Degeneration (CBD). Finally, we have tested the hypothesis
that there is a direct association between neuronal turnover of
24OHC and Tau with use of mouse models with increased or no
formation of Tau protein and increased production of 24OHC.
MATERIALS AND METHODS
Patients and CSF Sampling
This study involved CSF samples from patients from the
Neurology clinic, Karolinska University Hospital and the
Memory Clinic, University of California, San Francisco (UCSF)
Memory and Aging Center. All the investigations of the patients
and the analyses of their CSF were approved by the ethic
committees of the respective institutions. Informed consent was
obtained from the subjects.
In experiment 1, CSF from controls (i.e., subjects with
tension headache or benign parastesia), patients with early PD
[diagnostic criteria, see (10)] or CBS [diagnostic criteria see
(8)] were analyzed. In experiment 2, CSF from patients with
pathologically confirmed CBD from UCSF was studied. The
CBD diagnosis was made according to a previously described
procedure (9). Demographic information about the different
grups are presented in Table 1.
The CSF samples were obtained by lumbar puncture and
collected into polypropylene-tubes and subsequently centrifuged
(1,300–1,800 × g, 4◦C, 10min). The supernatant was carefully
pipetted off and dispensed in 500 µl aliquots before storage at
−80◦C. The time interval from collection to freezing was less
than 60min.
Animal Experiments
All the animal experiments were approved by the local Animal
Experimentation Ethics Committee.
Mouse Models With Overexpressed or No Tau Levels
Twelve weeks old male wildtype, tau KO and hTau OE
mice on a C57Bl6 background were used. Both mutant
Tau lines are deficient of murine Tau, but hTau OE
mice overexpress all six human Tau isoforms, leading to
gradual Tau pathology and behavioral deficits (11). Mice
were decapitated, cortical brain tissue samples dissected,
immediately frozen at −80◦C until analysis for oxysterol
levels.
Mouse Model With Overexpressed CYP46 and High
Levels of 24OHC in Circulation and Brain
Ten weeks old male mice with overexpression of CYP46 under
the β-actin promotor on a C57Bl6 background were used (12).
CYP46 is an enzyme synthetizing 24OHC and the CYP46 OE
mice have a 2-fold increase of 24OHC in the brain and a 4–6-
fold increase in serum (12). The mice have no obvious behavioral
phenotype. Cortical brain tissue was obtained as above and
analyzed for Tau species.
Analyses of Oxysterols
The analyses of 24OHC and 27OHC in CSF and mouse brain
tissue were performed by isotope dilution mass spectrometry
as described previously (2, 3, 13). In one CSF sample from
a CBS patient could only 24OHC, and not 27OHC, be
measured.
Analyses of Tau Species, Aβ42 and
Neurofilament
Tau, P-Thr181 Tau (commonly referred to as phospho-tau) and
Aβ42 analyzes in CSF samples from Karolinska were made
with enzyme-linked immunosorbent assay (ELISA) kits from
Innogenetics NV Ghent Belgium. CSF samples from USCF were
analyzed with the INNO-BIA AlzBio3 (Innogenetics, Ghent,
Belgium) platform to measure Tau, P-Thr181 Tau and Aβ42 and
the Uman Diagnostics ELISA kit (Umea, Sweden) to measure
neurofilament (NFL).
Levels of total Tau, 4R Tau and P-Ser202 Tau in cortical brain
tissue from wildtype and CYP46 OE mice were determined by
Western blotting and chemiluminiscence as previously described
(14). The primary antisera were kind gifts from Drs Peter Davies
and Rohan da Silva.
Statistics
Data are presented as mean ± S.D. Data was tested for
normality using the Kolmogorov–Smirnov test. When two
groups were compared, unpaired Student’s t-test was used.
When more than two groups were compared, statistical analyses
were made with one-way ANOVA followed by Dunnet’s test
or Kruskal Wallis test followed by Dunn’s test. Correlation
analyses were made with Pearson’s test followed by t-tests. All
statistical analyses weremade with GraphPADPrism (GraphPAD
Prism 5.0).
Frontiers in Neurology | www.frontiersin.org 2 September 2018 | Volume 9 | Article 756
Björkhem et al. 24OHC in CSF From PD and CBD
TABLE 1 | Demographics of examined controls (Ctrl) and patients with Parkinson’s Disease (PD), Corticobasal syndrome (CBS), and Corticobasal degeneration (CBD).
Age (years) Gender (M:F) Disease duration (years) Levodopa equivalent dose (LED)
Ctrl (n = 19) 58.2 ± 9.3 (45–82) 14:5 n/a n/a
PD (n = 30) 63.9 ± 10.8 (38–89) 21:9 0 0
CBS (n = 11) 68.9 ± 5.4 (60–81) 7:4 2.5 ± 1.7 (0–6) 144 ± 240 (0–764)
CBD (n = 8) 65.8 ± 3.1 (62–70) 6:2 n/k 0
Data are presented as the mean ± standard deviation and (range). n/a stands for not applicable and n/k for not known.
RESULTS
Levels of 24OHC and 27OHC in Patients
With PD or CBS
Patients with PD or CBS had significantly [F(2,61) 10.6; p< 0.001]
higher levels of 24OHC in CSF than those of the control
subjects (p < 0.05 and p < 0.001, respectively) (Figure 1A).
The data for 27OHC in CSF was not normally distributed,
but showed significant (Kruskal Wallis value 10.5) difference.
Pairwise comparisons showed that the levels were significantly
higher in the patients with CBS compared to controls (p < 0.01)
(Supplementary Figure 1A).
Correlations Between Levels of 24OHC or 27OHC
and Tau, P-Thr181 Tau and Aβ42 in CSF From Patients
With PD or CBS
Significant correlation was observed between levels of 24OHC
and Tau (r = 0.6, p < 0.001) in CSF from patients
with PD (Figure 1B). A similar correlation was observed
between 24OHC and P-Thr181 Tau (r = 0.62, p < 0.001)
(Supplementary Figure 2A), but not between 24OHC and Aβ42
(r = 0.21, p = 0.27) (Supplementary Figure 2C). There was a
lower, but significant (r = 0.38, p = 0.04 vs. r = 0.39, p = 0.03),
correlation between 27OHC and Tau and P-Thr181 Tau in CSF
from PD patients (Supplementary Figures 1B, 2B). There was
no significant (r = 0.27, p = 0.14) correlation between 27OHC
and Aβ42 in these patients (Supplementary Figure 2D).
There was a very high correlation between 24OHC and Tau (r
=0.98, p < 0.0001) as well as P-Thr181 Tau (r = 0.89, p < 0.001)
in patients with CBS (Figure 1C, Supplementary Figure 3A).
There was no significant (r = −0.16, p = 0.64) correlation
between 24OHC and Aβ42 (Supplementary Figure 3C).
There were no significant correlations between 27OHC
and Tau (r = 0.32, p = 0.37), P-Thr181 Tau (r = −0.37,
p = 0.3) or Aβ42 (r = 0.46, p = 0.18) in the CBS patients
(Supplementary Figures 1C, 3B,D).
Since CBS encompasses a diagnostically heterogeneous group
of patients (8, 9), we also evaluated CSF from pathologically
confirmed cases with CBD. In accordance with obtained data
from CBS patients, CBD patients showed a significant correlation
between 24OHC and Tau (r =0.84, p =0.008) (Figure 2A)
and a strong trend with P-Thr181 Tau (r = 0.69, p = 0.054)
(Figure 2B). There was no significant (r = 0.62, p = 0.10)
correlation between 24OHC and Aβ42 (Figure 2C). Measures
of NFL was also available from these CBD patients, but they
did not show (r = −0.35, p = 0.44) a significant correlation
to 24OHC (Figure 2D). There were no significant correlations
between 27OHC and Tau (r = 0.29, p = 0.48), P-Thr181 Tau
(r = −0.14, p = 0.75), Aβ42 (r = 0.17, p = 0.69) or NFL
(r =−0.24, p= 0.61) (Supplementary Figures 4A–D).
There was no correlation between 24OHC and Tau (r = 0.29,
p = 0.38), P-Thr181 Tau (r = 0.05, p = 0.89) or Aβ42 (r = 0.06,
p= 0.85) in control subjects. There was no significant correlation
between 24OHC levels and age in controls (r = 0.18, p = 0.45),
PD (r = 0.01, p = 0.95) or CBD (r = 0.09, p = 0.83) subjects,
whereas there was a positive correlation in CBS patients (r= 0.81,
p= 0.003).
Mouse Experiments Designed to Test the
Hypothesis That There Is a Direct
Interaction Between 24OHC and Tau
Turnover in the Brain
Based on the strong correlation between 24OHC levels and Tau
in CSF, we used mutant mouse models to examine whether there
could be a direct relation in their neuronal production. The
hypothesis that increased neuronal production of 24OHC affects
levels of Tau protein was tested in mice overexpressing CYP46.
It is known that these mice have a two-fold increased levels of
24OHC in the brain (10). However, there were no significant
differences between wildtype and CYP46OE mice in their levels
of total Tau, P-Ser202 Tau (CP-13) or 4R-Tau in cortical brain
tissue (Supplementary Figure 5). Vice versa, the hypothesis that
primary changes in the levels of Tau are able to affect levels
of 24OHC in the brain was tested with use of mice with no
(Tau KO mice) or increased (Tau OE) levels of Tau. As shown
in Supplementary Figure 6A, the levels of 24OHC were not
significantly [F(2,15) 0.07] different between these groups. There
was neither any significant (Kruskal Wallis value 3.8) alterations
in the levels of 27OHC in the genetically modified Tau mice
(Supplementary Figure 6B).
DISCUSSION
There is a continuous production of 24OHC in neuronal cells
and a flux of this oxysterol from the brain into the circulation
(1). A neurodegeneration will reduce this production resulting
in slightly reduced levels of 24OHC in the circulation (3). The
changes are however small and are difficult to use diagnostically.
In contrast a neurodegeneration results in increased levels of
24OHC in CSF most probably due to a release from dying
neuronal cells. This increase is sufficiently high to be used
diagnostically (15). Assuming that a considerable part of the
24OHC and Tau in CSF is released from dying neuronal cells,
a correlation between these two parameters can be expected
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FIGURE 1 | (A) Levels of 24OHC in CSF from controls or patients with
Parkinson’s disease (PD) or Corticobasal syndrome (CBS). (B,C) Correlations
between CSF levels of 24OHC and total Tau in PD (B) and CBS (C) patients.
In (A), #p < 0.05, ###p < 0.001 vs. control. In B,C, r values indicate
Pearson correlations and ***p < 0.001 significance.
in neurodegenerative disorders. Evidently, there was a strong
correlation between 24OHC and Tau in CSF from PD patients.
The CSF was collected at an early stage of PD and the patients
had no medication against PD. There was also a significant but
weak correlation between Tau and 27OHC in the PD patients.
The flux of 27OHC is likely to be dependent upon the rate of
FIGURE 2 | Correlations between CSF levels of 24OHC and total Tau (A),
P-Thr181-Tau (B), Aβ42 (C) or NFL (D) in patients with corticobasal degeneration
(CBD). r values indicate Pearson correlation and **p < 0.01 significance.
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metabolism of this oxysterol by the enzyme CYP7B1 (2). The
latter enzyme is mainly present in neuronal cells and a reduction
of the number of these cells can be expected to increase the level
of 27OHC into CSF. It should be pointed out that in contrast to
27OHC, 24OHC is not a substrate for CYP7B1. In view of this a
considerably lower correlation between 27OHC and Tau can be
expected. It should also be pointed out that due to the extensive
metabolism, the levels of 27OHC in the brain are much lower
than the corresponding levels of 24OHC (16).
The strongest finding here is the high correlation between
24OHC and Tau or P-Thr181-Tau in CSF from patients with
CBS and CBD. CBD is caused by accumulation predominantly
of 4R Tau. The underlying CBD pathology gives rise to a variety
of clinical presentations that encompass CBS, characterized by
levodopa resistant asymmetric dystonia or rigidity, bradykinesia
and myoclonus along with cortical symptoms such as apraxias,
speech difficulties and alien limb phenomenona. However,
CBD also includes a syndrome clinically similar to progressive
supranuclear palsy (PSPS-CBD), a frontotemporal behavioral
variant (FTD-CBD) and a variant with progressive non-fluent
aphasia (PNFA-CBD). Due to this heterogeneity in presentation,
a clinical diagnosis of CBD is often difficult and many patients
will receive an ante mortem diagnosis that is altered upon post
mortem examination (8, 9). In our first experiment we examined
CSF from living patients with a typical CBS presentation,
but could later verify the strong correlation between 24OHC
and Tau in another cohort of pathologically confirmed CBD
patients. Another difference between these cohorts were that
the patients in the CBD cohort were not on any medication
against parkinsonism which could potentially influence oxysterol
levels.
The very high correlation between 24OHC and Tau led us
to test the hypothesis that there is a direct interaction between
the neuronal production of the two factors. Indeed, based
on experiments with mouse models the possibility has been
discussed that there may be a causal link between CYP46A1
protein content and memory impairment that result from Tau
pathology (17).
However, experiments with a mouse model with high levels of
24OHC and mouse models with increased or no levels of Tau did
not give support for this hypothesis. Thus, 24OHC is not likely to
be a driving force for increased production of Tau and, vice versa,
Tau is not likely to directly determine the production of 24OHC.
It is noteworthy that young mice were used in our studies to
avoid indirect influence of aging, but it may also turn out that
reciprocal changes in 24OHC and Tau are only evident in older
mice. Nonetheless, it seems likely that the correlation between the
two factors in the patients is secondary to neurodegeneration,
in PD as well as CBD patients. In theory, a high correlation
between 24OHC and Tau can be expected if there is a very rapid
decomposition of individual neuronal cells with a simultaneous
release of both 24OHC and Tau. Accordingly, a higher correlation
was seen in CBS/CBD than in PD patients, likely to reflect the
more aggressive neurodegeneration in CBD/CBS.
In conclusion, CSF levels of 24OHC are elevated, at group
level, in PD, CBS, and CBD, and show a very strong correlation
to Tau. Future studies will evaluate whether 24OHC and Tau
interact synergistically in pathophysiological events underlying
PD or CBD. It will also be interesting to study whether there is
a correlation between 24OHC and α-synuclein and to measure
24OHC in the same individual at different disease stages in
longitudinal cohort studies.
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Supplementary Figure 1 | (A) Levels of 27OHC in CSF from controls or patients
with Parkinson’s disease (PD) or Corticobasal syndrome (CBS). (B,C) Correlations
between CSF levels of 27OHC and total Tau in PD (B) and CBS (C) patients. In A,
#p < 0.05 vs. control. In B,C, r values indicate Pearson correlations and
∗p < 0.05 significance.
Supplementary Figure 2 | Correlations between CSF levels of 24OHC (A,C) or
27OHC (B,D) and P-Thr181-Tau (A,B) or Aβ42 (C,D) in patients with PD. r values
indicate Pearson correlation and ∗p < 0.05, ∗∗∗p < 0.001 significance.
Supplementary Figure 3 | Correlations between CSF levels of 24OHC (A,C) or
27OHC (B,D) and P-Thr181-Tau (A,B) or Aβ42 (C,D) in patients with CBS. r
values indicate Pearson correlation and ∗∗∗p < 0.001 significance.
Supplementary Figure 4 | Correlations between CSF levels of 27OHC and total
Tau (A), P-Thr181-Tau (B), Aβ42 (C) or NFL (D) in patients with CBD. r values
indicate Pearson correlations.
Supplementary Figure 5 | Relative levels of total Tau, P-Ser202-Tau (“CP13”)
and 4-repeat Tau in cortical brain tissue of wildtype (WT) mice and mice with an
overexpression of CYP46 and increased levels of 24OHC.
Supplementary Figure 6 | Levels of 24OHC (A) and 27OHC (B) in cortical
brain tissue of wildtype (WT) mice or with increased (Tau OE) or no (Tau KO)
levels of Tau.
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